UPMC backs cancer diagnostics startup Cernostics
Cernostics is part of the wave of oncology that looks at cancer at the tissue and cellular level instead of focusing on the location of the tumor — lung, stomach, pancreas.
Diagnostic developer with faster, more accurate esophageal cancer test nets follow-on funding
Esophageal cancer is one of the fastest growing cancers in western countries and has one of the highest mortality rates among cancers. About 17,990 new cases are diagnosed in the United States each year, according to data from the American Cancer Society. More than 15,000 people die from esophageal cancer annually. Medical device company Cernostics […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Esophageal cancer risk test developer gets new funding
A molecular diagnostic testing company has received $55,000 from a Pennsylvania economic development agency to develop a test to determine a patient’s risk for esophageal cancer if they have Barrett’s esophagus. The company is collaborating with Geisinger Health System on the test. Ben Franklin Technology Partners of Northeastern Pennsylvania has invested a total of $100,000 […]
Pathology imaging firm Cernostics pulls in $2.6M
Slightly under-the-radar Cernostics Inc. has raised $2.6 million in equity, debt and options, according to a regulatory filing with the Securities and Exchange Commission. The newly rechristened Cernostics was previously known as Cernostics Pathology Inc., including in 2008 when it was spun off from Pittsburgh-based Cellumen Inc. At the time of the spinoff, Cernostics’ aim […]